FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1262-1263 September 20, 2007 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Khuri, F. R. PubMed Citation

To the Editor: Khuri (June 14 issue)¹ highlights safety concerns regarding the use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. The studies that have given rise to these concerns used significantly higher hemoglobin targets than those used in the community or recommended in widely used guidelines,^2,3 and thus do not reflect the current standard of care. The only study that did not use an excessively high hemoglobin target has not been published and cannot be accurately reviewed.

In these studies, treatment with ESAs was initiated in patients with hemoglobin levels as high as 14.5 g per deciliter. Many of . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.